J. Hohneker

发表

The effects of food and divided dosing on the bioavailability of oral vinorelbine

R. Donehower, E. Rowinsky, B. Lubejko, 1996, Cancer Chemotherapy and Pharmacology.

Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop

John A Wagner, S. Nass, P. LoRusso, 2012, Clinical Cancer Research.

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors

D. V. Von Hoff, L. Smith, H. Burris, 2004, Investigational New Drugs.

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.

J. Crawford, J. Schiller, M. O'Rourke, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.

G. Warsi, N. Gabrail, E. Miles, 2006, The journal of supportive oncology.

FDA drug information that never reaches clinicians.

J. Hohneker, G. Gruia, S. Ericson, 2010, The New England journal of medicine.

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

B. Weber, L. Hutchins, C. Vogel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

E. Perez, E. Tan-chiu, A. Brufsky, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.

C. Vogel, J. Hohneker, L. Lacerna, 2004, The oncologist.

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

D. V. Von Hoff, L. Smetzer, H. Burris, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of 1843 U 89 , a Noncompetitive Inhibitor of Thymidylate Synthase , in Patients with Advanced Solid Malignancies 1

L. Smetzer, H. Burris, D. V. Hoff, 2001 .

A summary of vinorelbine (Navelbine) safety data from North American clinical trials.

J. Hohneker, 1994, Seminars in oncology.

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion

R. Schilsky, M. Ratain, N. Vogelzang, 2004, Cancer Chemotherapy and Pharmacology.

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

L. Hutchins, C. Vogel, S. Jones, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.

E. Vokes, R. Rosenberg, R. Gralla, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CHAPTER 26: GASTROINTESTINAL TOXICITIES

P. Wissel, J. Hohneker, T. Lampkin, 2001 .

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

L. Grochow, D. Noe, S. Khor, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.

R. Schilsky, H. Burris, S. Mani, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.

R. Schilsky, M. Ratain, R. Diasio, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.

R. Schilsky, S. Mani, M. O'Rourke, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.

E. Vokes, R. Rosenberg, R. Gralla, 1994, Seminars in oncology.

Final 5‐year results of Z‐FAST trial

E. Perez, L. Bosserman, C. Vogel, 2012, Cancer.

High-dose (HD) imatinib in patients (pts) with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial

H. Kantarjian, J. Cortes, F. Giles, 2005 .

Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer

E. Winer, D. Hayes, U. Matulonis, 1999, Cancer Chemotherapy and Pharmacology.

EPO906 (epothilone B): a promising novel microtubule stabilizer.

M. Wartmann, J. Hohneker, J. Rothermel, 2003, Seminars in oncology.

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

E. Eriksen, R. Weitzman, J. Hohneker, 2007, Critical reviews in oncology/hematology.

Clinical Development of Eniluracil/Fluorouracil: an Oral Treatment for Patients with Solid Tumors

J. Hohneker, J. Levin, 2000, Investigational New Drugs.

Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

A. Benson, E. Mitchell, P. Ritch, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor

H. Roberts, H R Roberts, B G Macik, 1989, American journal of hematology.

Saponification of dimethyl cis-2,6-diphenyl-4-oxocyclohexane-1,1-dicarboxylate. A reinvestigation

J. Hohneker, K. McDaniel, D. S. Moore, 1982 .

Allopurinol: intravenous use for prevention and treatment of hyperuricemia.

D. Cederberg, J. Hohneker, R. Smalley, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.

E. Winer, D. Ettinger, D. Noe, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.

J. Wharton, D. Gershenson, T. Burke, 1998, Gynecologic oncology.

Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer

L. Grochow, D. Trump, D. Spriggs, 2004, Investigational New Drugs.

Perspectives on adherence and persistence with oral medications for cancer treatment.

J. Hohneker, P. Brandt, Shilpa Shah-Mehta, 2011, Journal of oncology practice.

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

F. Greenway, D. Heimburger, G. Warsi, 2006, International Journal of Obesity.

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.

L. Grochow, R. Diasio, S. Khor, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.

J. Hohneker, L. Lacerna, 2003, Seminars in oncology.

Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.

F. Shepherd, L. Souhami, J. Viallet, 1994, Seminars in Oncology.